2021
-
December 23, 2021 Corporate PDF249 KB
-
December 22, 2021 Pharmaceuticals PDF268 KB
Zogenix Submission of New Drug Application for ZX008 (Fenfluramine Hydrochloride) in Japan
-
December 10, 2021 Pharmaceuticals PDF320 KB
Coverage in NHI Drug Price Listing and Launch Date of TADALAFIL Tablets 2.5 mg/5 mg ZA "SIOE"
-
November 29, 2021 Pharmaceuticals PDF155 KB
-
November 25, 2021 Pharmaceuticals PDF233 KB
-
November 10, 2021 R & D PDF235 KB
Nippon Shinyaku enter into an Option Agreement for DYN101 in Japan
-
November 10, 2021 Management & Finance PDF644 KB
Outline of Consolidated Financial Results for the Second Quarter Ended September 30, 2021
-
November 04, 2021 Corporate PDF297 KB
-
October 18, 2021 Management & Finance PDF242 KB
Notice on the Selection to Apply to New Market Segment “Prime Market” on the Tokyo Stock Exchange
-
September 22, 2021 Pharmaceuticals PDF263 KB
-
September 17, 2021 Pharmaceuticals PDF276 KB
-
August 25, 2021 Pharmaceuticals PDF254 KB
-
August 10, 2021 Management & Finance PDF215 KB
Outline of Consolidated Financial Results for the First Quarter Ended June 30, 2021
-
July 14, 2021 Corporate PDF270 KB
-
July 01, 2021 Pharmaceuticals PDF299 KB
-
June 25, 2021 Pharmaceuticals PDF262 KB
Submission of New Drug Application for NS-065/NCNP-01 (viltolarsen) in China
-
June 21, 2021 Pharmaceuticals PDF263 KB
-
May 14, 2021 Management & Finance
Outline of Consolidated Financial Results for the Year Ended March 31, 2021
-
May 12, 2021 Pharmaceuticals PDF261 KB
-
March 23, 2021 Pharmaceuticals PDF263 KB
(Media)MHLW approval of Vidaza(azacitidine) for the Treatment of Acute Myeloid Leukemia
-
March 18, 2021 Management & Finance PDF233 KB
-
March 16, 2021 Management & Finance PDF311 KB
(Media)Nippon Shinyaku Announces Changes to Representative Directors and Members of the Board
-
February 08, 2021 Management & Finance
Outline of Consolidated Financial Results for the Third Quarter Ended December 31, 2020